{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T06:11:57Z","timestamp":1793427117780,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.euo.2023.07.013","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T03:46:27Z","timestamp":1691811987000},"page":"179-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis"],"prefix":"10.1016","volume":"7","author":[{"given":"Carlo","family":"Messina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio Francesco","family":"Giunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Signori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Elena","family":"Rebuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Maniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Cattrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fornarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bauckneht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Greystoke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Oing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4668-4765","authenticated-orcid":false,"given":"Pasquale","family":"Rescigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2023.07.013_b0005","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.3390\/cancers13194771","article-title":"Molecular characterization of prostate cancers in the precision medicine era","volume":"13","author":"Giunta","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2023.07.013_b0010","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2023.07.013_b0015","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","article-title":"Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study","volume":"26","author":"Abida","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2023.07.013_b0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2010.06.017","article-title":"The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets","volume":"39","author":"Krishnakumar","year":"2010","journal-title":"Mol Cell"},{"key":"10.1016\/j.euo.2023.07.013_b0025","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: PARP1 and beyond","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.euo.2023.07.013_b0030","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","article-title":"Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer","volume":"8","author":"Asim","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2023.07.013_b0035","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","article-title":"Dual roles of PARP-1 promote cancer growth and progression","volume":"2","author":"Schiewer","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.euo.2023.07.013_b0040","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo- controlled, phase 2 trial","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2023.07.013_b0045","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.3390\/cancers13225830","article-title":"Homologous recombination repair gene mutation characterization by liquid biopsy: a phase II trial of olaparib and abiraterone in metastatic castrate-resistant prostate cancer","volume":"13","author":"Carr","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2023.07.013_b0050","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"10.1016\/j.euo.2023.07.013_b0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2023.07.013_b0060","unstructured":"Higgins JPT, Green S, editors. Assessing the quality of a body of evidence. In: Cochrane handbook for systematic reviews of interventions, volume 5.1.0. New York, NY: John Wiley & Sons; 2011, p. 361\u20136."},{"key":"10.1016\/j.euo.2023.07.013_b0065","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2023.07.013_b0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1258\/1355819021927674","article-title":"Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice","volume":"7","author":"Higgins","year":"2002","journal-title":"J Health Serv Res Policy"},{"key":"10.1016\/j.euo.2023.07.013_b0075","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"Suppl 7","key":"10.1016\/j.euo.2023.07.013_b0080","doi-asserted-by":"crossref","first-page":"S1160","DOI":"10.1016\/j.annonc.2022.07.1945","article-title":"1357O \u2013 Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"33","author":"Saad","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2023.07.013_b0085","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2023.07.013_b0090","article-title":"TALAPRO-2: phase 3 study of talazoparib (TALA)enzalutamide (ENZA) versus placebo (PBO)ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Agarwal","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.07.013_b0095","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2023.07.013_b0100","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.3390\/cancers12092467","article-title":"Second-generation antiandrogen therapy radiosensitizes prostate cancer regardless of castration state through inhibition of DNA double strand break repair","volume":"12","author":"Elsesy","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2023.07.013_b0105","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1158\/2159-8290.CD-21-0007","article-title":"Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial","volume":"11","author":"Carreira","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.euo.2023.07.013_b0110","doi-asserted-by":"crossref","first-page":"6677","DOI":"10.1158\/1078-0432.CCR-21-2199","article-title":"Response to rucaparib in BRCA-mutant metastatic castration-resistant prostate cancer identified by genomic testing in the TRITON2 study","volume":"27","author":"Loehr","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2023.07.013_b0115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1158\/1078-0432.CCR-22-0931","article-title":"Detection of BRCA1, BRCA2, and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound","volume":"29","author":"Chi","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"Suppl 9","key":"10.1016\/j.euo.2023.07.013_b0120","doi-asserted-by":"crossref","first-page":"S1495","DOI":"10.1016\/j.annonc.2022.10.194","article-title":"157O\u2013 Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"33","author":"Oya","year":"2022","journal-title":"Ann Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2023.07.013_b0125","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2023.41.6_suppl.172","volume":"41","author":"Castro","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.07.013_b0130","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2023.07.013_b0135","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.clgc.2022.07.005","article-title":"Review of toxicities of PARP inhibitors in metastatic castrate resistant prostate cancer","volume":"21","author":"Nindra","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2023.07.013_b0140","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.euf.2022.08.007","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: a systematic review and network meta-analysis","volume":"9","author":"Mandel","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2023.07.013_b0145","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1172\/JCI125184","article-title":"Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer","volume":"128","author":"Rodrigues","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.euo.2023.07.013_b0150","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2023.07.013_b0155","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.euo.2022.04.004","article-title":"Immune biomarkers in metastatic castration-resistant prostate cancer","volume":"5","author":"Fenor de la Maza","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2023.07.013_b0160","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.3390\/ijms23094709","article-title":"Beyond BRCA: the emerging significance of DNA damage response and personalized treatment in pancreatic and prostate cancer patients","volume":"23","author":"Dalmasso","year":"2022","journal-title":"Int J Mol Sci"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931123001554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931123001554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T06:23:24Z","timestamp":1711261404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931123001554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2588931123001554"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2023.07.013","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2023.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}